HEMGENIX ®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases "CSL is humbled and honored to receive a Prix Galien award for ...
Management reaffirmed guidance for fiscal 2025, expecting revenue growth of 5% to 7% and NPATA between AUD 3.2 billion to AUD 3.3 billion at constant currency. CSL Behring is anticipated to sustain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results